Literature DB >> 30088118

Balloon pulmonary angioplasty is a promising option in thalassemic patients with inoperable chronic thromboembolic pulmonary hypertension.

Panagiotis Karyofyllis1, Dimitris Tsiapras2, Varvara Papadopoulou3, Michael D Diamantidis4, Paraskevi Fotiou4, Eftychia Demerouti2, Vassilis Voudris3.   

Abstract

Pulmonary hypertension (PH), a serious disorder with a high morbidity and mortality rate, is known to occur in a number of unrelated systemic diseases. β-Thalassaemia, among other haematological disorders, develop PH which is not an infrequent finding and worsens the prognosis. Haemolysis, iron overload and hypercoagulable state are among the main pathogenetic mechanisms. Haemoglobinopathies and congenital haemolytic anaemia constitute a unique patients population more predisposed to developing chronic thromboembolic pulmonary hypertension (CTEPH). Although pulmonary endarterectomy is accepted as the best treatment for CTEPH, surgery in these patients poses significant practical challenges given the distinct nature of the disease. As drug therapy is not expected to offer relief from the mechanical obstructions of pulmonary arteries and the use of specific pulmonary arterial hypertension drugs is not established in thalassaemia patients, the novel technique of balloon pulmonary angioplasty (BPA) may emerge as a new therapeutic option for patients with inoperable CTEPH and thalassaemia. We are reporting the case of a thalassaemic patient with a history of splenectomy suffering from progressive severe pulmonary hypertension related to chronic thromboembolic disease, who was successfully treated by BPA with substantial improvement.

Entities:  

Keywords:  Balloon pulmonary angioplasty (BPA); Chronic thromboembolic pulmonary hypertension (CTEPH); Hemoglobinopathies; Thalassemia

Mesh:

Year:  2018        PMID: 30088118     DOI: 10.1007/s11239-018-1720-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

Review 1.  Chronic thromboembolic pulmonary hypertension.

Authors:  P F Fedullo; W R Auger; K M Kerr; L J Rubin
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Bastiaan E Scholzel; Martijn C Post; H W Thijs Plokker; Repke J Snijder
Journal:  Lung       Date:  2011-12-08       Impact factor: 2.584

Review 3.  Thrombosis in thalassemia: why are we so concerned?

Authors:  Khaled M Musallam; Ali T Taher
Journal:  Hemoglobin       Date:  2011-09-12       Impact factor: 0.849

4.  Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.

Authors:  Joanna Pepke-Zaba; Marion Delcroix; Irene Lang; Eckhard Mayer; Pavel Jansa; David Ambroz; Carmen Treacy; Andrea M D'Armini; Marco Morsolini; Repke Snijder; Paul Bresser; Adam Torbicki; Bent Kristensen; Jerzy Lewczuk; Iveta Simkova; Joan A Barberà; Marc de Perrot; Marius M Hoeper; Sean Gaine; Rudolf Speich; Miguel A Gomez-Sanchez; Gabor Kovacs; Abdul Monem Hamid; Xavier Jaïs; Gérald Simonneau
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

5.  Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report.

Authors:  Simona Roggero; Silvia Vullo; Gisella Volpe; Antonio Piga; Carlo Albera
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 6.  Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension.

Authors:  David Jenkins; Michael Madani; Elie Fadel; Andrea Maria D'Armini; Eckhard Mayer
Journal:  Eur Respir Rev       Date:  2017-03-15

Review 7.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

Review 8.  Heart disease in thalassemia intermedia: a review of the underlying pathophysiology.

Authors:  Athanasios Aessopos; Maria Kati; Dimitrios Farmakis
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

9.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

10.  Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.

Authors:  Ali T Taher; Khaled M Musallam; Mehran Karimi; Amal El-Beshlawy; Khawla Belhoul; Shahina Daar; Mohamed-SalahEldin Saned; Abdul-Hamid El-Chafic; Maria R Fasulo; Maria D Cappellini
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.